Блокатор рецепторов ангиотензина II олмесартан в прерывании сердечно-сосудистого и кардиоренального континуума: антигипертензивные и нефропротективные эффекты. Часть 1

Обложка

Цитировать

Полный текст

Аннотация

В статье представлен обзор эффективности и переносимости одного из представителей класса блокаторов рецепторов ангиотензина II - олмесартана медоксомила (Кардосал). Проанализированы фармакологические особенности и ангигипертензивная активность олмесартана медоксомила при монотерапии, в комбинации с другими антигипертензивными препаратами, у разных групп пациентов. В статье изложены нефропротективные свойства препарата, профиль его безопасности. Также рассматриваются причины низкой приверженности терапии пациентов, страдающих артериальной гипертонией.

Об авторах

Марина Геннадьевна Бубнова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза

Список литературы

  1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the on management of arterial hypertension. Eur Heart J 2013. doi: 10.1093/eurheartj/eht151.
  2. James P.A, Oparil S, Carter B.L et al. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014. doi: 10.1001/jama.2013.284427.
  3. Mancini G.B.J, Etminan M, Zhang B et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. JACC 2006; 47 (12): 2554-60.
  4. Ferrario C.M, Strawn W.B. Role of the renin - angiotensin - aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98 (1): 121-8.
  5. Jacoby D.S, Rader D.J. Renin - angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 163 (10): 1155-64.
  6. Dzau V. The cardiovascular continuum and renin - angiotensin - aldosterone system blockade. J Hypertens 2005; 23 (Suppl. 1): S9-17.
  7. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21 (1): 20-7.
  8. Touyz R.M. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90 (4): 449-55.
  9. Papademetriou V. Inhibition of the renin - angiotensin - aldosterone system to prevent ischemic and atherothrombotic events. Am Heart J 2009; 157 (6 Suppl. 1): S25-30.
  10. Turnbull F. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
  11. Carey R.M, Wang Z.Q, Sigary H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-63.
  12. Scott L.J, McCormack P.L. Olmesartan: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
  13. Mire D.E, Silfani T.N, Pugsley M.K. A Review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585-93.
  14. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS0866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-8.
  15. Warne G.T, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-53.
  16. Agata J, Ura N, Yoshida H et al. Олмесартан - блокатор рецепторов к ангиотензину II, обладающий ингибиторным эффектом на ангиотензинпревращающий фермент. Hypertens Res 2006; 29 (11): 865-74.
  17. Brunner H.R, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001; 19 (S1): S15-S20.
  18. Giles T.D, Robinson T.D. Effects of Olmesartan Medoxomil on Systolic Blood Pressure and Pulse Pressure in the Management of Hypertension. Am J Hypertens 2004;17: 690-5.
  19. Ichikawa S, Takayama Y. Long - term effects of Olmesartan, an Ang II receptor antagonist, on blood pressure and the renin - angiotensin - aldosterone system in hypertensive patients. Hypertens Res 2001; 24 (4): 641-6.
  20. Oparil S, Williams D, Chrysant S.G et al. Comparative efficacy of Olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3 (5): 283-92.
  21. Brunner H.R, Stumpe K.O, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419-30.
  22. Scott L.J, McCormack P.L. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
  23. Heagerty A.M, Mallion J.M. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26: 61-76.
  24. Mallion J.M, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25: 2168-77.
  25. Малакко Э., Омбони С., Вульпе М. и др. Антигипертензивная эффективность и безопасность олмесартана медоксомила и рамиприла у пожилых пациентов с мягкой и умеренной эссенциальной гипертензией: результаты исследования ESPORT. Рос. кардиол. журн. 2012; 1 (93): 8-18.
  26. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early - stage type-2 diabetics with hypertension. Hypertens Res 2008; 31 (1): 7-13.
  27. Menne J, Jr Izzo J.L, Ito S et al. For the ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012, 30: 811-8.
  28. Yanagi M, Tamura K, Fujikawa T et al. The ahgionetsin II type 1 receptor bloker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2012; 15.doi: 10.1038/hr.2012.184.
  29. Hermida R.C, Ayala D.E, Mojon A, Fernandez J.R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-21.
  30. Chrysant S.G et al. Evaluation of antihypertensive therapy with the combination of Olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9.
  31. Rump L.C, Ambrosioni E. Initial combination therapy with Olmesartan/hydrochlorothiazide shows superior blood pressure control rate in moderate to severe. Hypertension ESC/ESH 14th Annual Meeting, Paris, 2004.
  32. Ram C.V. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial - design studies. J Clin Hypertens 2004; 6 (10): 569-77.
  33. Palatini P. Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. J Clin Hypertens 2005; 7 (2): 96-101.
  34. Chrysant S.G, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double - blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587-604.
  35. Klag M.J, Whelton P.K, Randall B.L et al. Blood pressure and end - stage renal disease in men. N Engl J Med 1996; 334: 13-8.
  36. Koc Y, Mazi E, Sakaci T. Effect of olmesartan on cystain C level in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 55 (12): 1388-94.
  37. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blokade reduces (itra) renal vascular resistence in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 (4): 1135-40.
  38. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117-8.
  39. Rodrìguez-Iturbe B, Sato T, Quiroz Y. AT1-receptor blockade prevents proteinuria, renal failure, hyperlipidemia and glomerulosclerosis in the Imai rat. Kidney Int 2004; 66: 668-75.
  40. Yoshida K, Xu H.L, Kawamura T et al. Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism in Rats With Chronic Renal Failure. J Cardiovasc Pharmacol 2002; 40: 533-42.
  41. Koga K, Yamagishi S, Takeuchi M et al. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 2002; 8 (10): 591-9.
  42. Püchler K, Laeis P, Stumpe K.O. Blood pressure response, but not adverse event Incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (S.1): S41-S48.
  43. Бубнова М.Г., Аронов Д.М.. Эффективность фиксированной комбинации лозартана и гидрохлоротиазида у больных артериальной гипертонией при разном типе ремоделирования левого желудочка в наблюдательной программе ПРОГНОЗ. CardioСоматика. 2012; 3: 32-41.
  44. Rumsfeld J.S, Masoudi F.A. Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166: 1836-41.
  45. Breekveldt-Postma N.S, Siiskonen S.J, Penning - van Beest F.J.A, et al. Non - persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Value Health 2006; 9: A339.
  46. Perreault S, Dragomir A, Roy L et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69: 74-84.
  47. Perreault S, Dragomir A, Roy L et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266: 207-18.
  48. Kettani F.Z, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-20.

© ООО "Эко-Вектор", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах